Remedicalizing cannabis : science, industry, and drug policy / Suzanne Taylor.

By:

Taylor, Suzanne (Research fellow) [Author]

Material type: Text

text

Media type:

computer

Carrier type:

online resource

ISBN:

9780228013501
9780228013495

Subject(s):

Genre/Form:

Electronic Books.

LOC classification:

RM666 .R464 2022

Online resources:

Click to access digital title | log in using your CIU ID number and my.ciu.edu password.

Available additional physical forms:

Contents:

Cannabis in the Clinic: Clinical Pharmacology and the Therapeutic Applications of Cannabis, 1973-82 -- Evidence-Based Policy? The Development of Expert Committees, 1972-82 -- Industrializing Cannabis: The Pharmaceutical Industry and the Remedicalization of Cannabis, 1973-2001 -- Forces of Necessity: Lay Advocacy and the Remedicalization of Cannabis, 1973-2001 -- Establishing Therapeutic Cannabis: The Role of Expert Advice, 1997-2001 -- From Anecdotal to Evidence-Based Medicine: The Role of Clinical Trials, 1995-2005 -- Accessing Cannabis-Based Medicinal Products (CBMPS), 2009-21.

Subject: "When cannabis tincture was withdrawn as a medical product in the UK in 1973, cannabis became regulated solely as an illicit drug. Within a decade cannabis-based drugs were back in the clinic. The UK is one of the biggest producers of medicinal cannabis, but few patients have access to these medicines. High-profile cases of parents campaigning for access to cannabis oil for severe and rare forms of epilepsy in their children are the most recent in a long line of controversies over cannabis and cannabis-based medicines. With mounting questions about patient access, the effectiveness of international drug control systems, and the role of expert advice, it is crucial to understand how we have arrived at this situation. While the historical literature has focused on cannabis as an illicit substance, Remedicalising Cannabis considers the botanical product and its potential to yield medical applications. Investigating the remedicalization of cannabis, Taylor explores the process whereby boundaries shift between illicit drug and licit medicine. Basing her arguments on archival material from expert committees, researchers, and activists and in-depth interviews with key players, Suzanne Taylor traces the issues and interests involved in this process, demonstrating the important roles of changing scientific knowledge, expert advice, industry, clinical trials, and patient activism. Remedicalising Cannabis investigates the evolving tensions that have brought us to the current situation and demonstrates the role of history in understanding today's debates about cannabis."--

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Collection	Call number	URL	Status	Date due	Barcode
Online Book (LOGIN USING YOUR MY CIU LOGIN AND PASSWORD)	G. Allen Fleece Library ONLINE	Non-fiction	RM666.266 (Browse shelf(Opens below))	Link to resource	Available		on1330713484

Includes bibliographies and index.

Understanding Cannabis: Pharmacology, Laboratory Research, and Drug Control, 1964-82 -- Cannabis in the Clinic: Clinical Pharmacology and the Therapeutic Applications of Cannabis, 1973-82 -- Evidence-Based Policy? The Development of Expert Committees, 1972-82 -- Industrializing Cannabis: The Pharmaceutical Industry and the Remedicalization of Cannabis, 1973-2001 -- Forces of Necessity: Lay Advocacy and the Remedicalization of Cannabis, 1973-2001 -- Establishing Therapeutic Cannabis: The Role of Expert Advice, 1997-2001 -- From Anecdotal to Evidence-Based Medicine: The Role of Clinical Trials, 1995-2005 -- Accessing Cannabis-Based Medicinal Products (CBMPS), 2009-21.

"When cannabis tincture was withdrawn as a medical product in the UK in 1973, cannabis became regulated solely as an illicit drug. Within a decade cannabis-based drugs were back in the clinic. The UK is one of the biggest producers of medicinal cannabis, but few patients have access to these medicines. High-profile cases of parents campaigning for access to cannabis oil for severe and rare forms of epilepsy in their children are the most recent in a long line of controversies over cannabis and cannabis-based medicines. With mounting questions about patient access, the effectiveness of international drug control systems, and the role of expert advice, it is crucial to understand how we have arrived at this situation. While the historical literature has focused on cannabis as an illicit substance, Remedicalising Cannabis considers the botanical product and its potential to yield medical applications. Investigating the remedicalization of cannabis, Taylor explores the process whereby boundaries shift between illicit drug and licit medicine. Basing her arguments on archival material from expert committees, researchers, and activists and in-depth interviews with key players, Suzanne Taylor traces the issues and interests involved in this process, demonstrating the important roles of changing scientific knowledge, expert advice, industry, clinical trials, and patient activism. Remedicalising Cannabis investigates the evolving tensions that have brought us to the current situation and demonstrates the role of history in understanding today's debates about cannabis."--

https://lib.ciu.edu/copyright-request-form

There are no comments on this title.

to post a comment.